NIH

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Retrieved on: 
Thursday, February 1, 2024

This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.

Key Points: 
  • This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
  • Then, a radionuclide held tightly by Perspective’s proprietary chelator attached to an Adma group is administered.
  • The research conducted at Stony Brook University refines the understanding of the potential of the proprietary CB7-Adma pre-targeting platform for image-guided radionuclide therapy for oncology.
  • The technology was first described by Stony Brook University researchers, Jacob L. Houghton, Ph.D. and Vilma I.J.

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Retrieved on: 
Wednesday, January 31, 2024

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023.

Key Points: 
  • NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2023.
  • Mesoblast will provide the Phase 3 trial protocol to FDA ahead of the upcoming meeting this quarter.
  • Mesoblast will meet with FDA this quarter to address potential pathways to approval for REVASCOR under our Regenerative Medicine Advanced Therapies (RMAT) designation.
  • Revenue from royalties on sales of TEMCELL® HS Inj.5 sold in Japan by our licensee for the quarter were US$1.5 million.

Brain Training Improves Social Determinants of Health

Retrieved on: 
Wednesday, January 31, 2024

According to Posit Science , the maker of the BrainHQ brain fitness program, that presentation will highlight the role of brain training in addressing non-medical factors that lead to better health.

Key Points: 
  • According to Posit Science , the maker of the BrainHQ brain fitness program, that presentation will highlight the role of brain training in addressing non-medical factors that lead to better health.
  • In recent years, Medicare Advantage (MA) plans have improved their offerings of supplemental benefits to address so-called “Social Determinants of Health” (SDoH) – non-medical factors and conditions (e.g., access to nutrition, transportation, safety, and social engagement) which have been shown to impact health outcomes.
  • MA plans have added a variety of Supplemental Benefits to provide Medicare members with SDoH services (e.g., meals, transportation to appointments, home safety risk reductions, and socialization opportunities).
  • Both are pioneers in the field of brain training, and each has led numerous studies.

Maxim Biomedical, Inc. Secures Second NIH RADx Tech High Performance Award for Continued Development of At-Home FiarFly™ Reader and COVID-19 & Flu A/B Rapid Test

Retrieved on: 
Thursday, February 1, 2024

ROCKVILLE, Md., Feb. 1, 2024 /PRNewswire/ -- MaximBio, a leading innovator in next-generation healthcare diagnostic technologies, is pleased to announce that it has been granted a second follow-on award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for the continued development of its revolutionary FiarFly™ reader and COVID-19 & Flu A/B multiplex test.

Key Points: 
  • ROCKVILLE, Md., Feb. 1, 2024 /PRNewswire/ -- MaximBio, a leading innovator in next-generation healthcare diagnostic technologies, is pleased to announce that it has been granted a second follow-on award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for the continued development of its revolutionary FiarFly™ reader and COVID-19 & Flu A/B multiplex test.
  • This additional Phase 2 award, totaling approximately $4.4 million, will be used to accelerate the development of the FiarFly™ reader and COVID-19 & Flu A/B multiplex test and quickly prepare for clinical trials targeting this influenza season.
  • "We are honored to receive another award from the NIH RADx Tech program and continue to build upon our successful programs with the NIH," said Jonathan Maa, Chief Operating Officer at MaximBio.
  • This award underscores MaximBio's commitment to advancing cutting-edge diagnostic solutions to address the ongoing challenges posed by multiple infectious diseases and increasing access to high-quality, rapid testing solutions.

Beacon Biosignals welcomes David Matthews, PhD, as Chief Business Officer

Retrieved on: 
Thursday, February 1, 2024

BOSTON, Feb. 1, 2024 /PRNewswire/ -- Beacon Biosignals, a leading computational neurodiagnostics and EEG analytics company, has appointed David Matthews, PhD, as Chief Business Officer to oversee commercial and strategic activities.

Key Points: 
  • Beacon Biosignals partners with top biopharma companies to better understand brain health using clinical-grade EEG and AI-powered analysis.
  • The company's Dreem 3S wearable medical device enables validated sleep endpoints at-home and unlocks a scale of brain activity data never before available.
  • Dr. Matthews will draw on his deep expertise in healthcare strategy, commercial development, and computational neuroscience to create new partnerships, expand relationships, and drive continued innovation for Beacon Biosignals through the company's next phase of growth.
  • "We are thrilled to welcome David to our leadership team," said Jacob Donoghue, MD PhD, CEO of Beacon Biosignals.

Advaita Bio awarded $1.7 million NIH study to pioneer platform for the analysis of single-cell data

Retrieved on: 
Tuesday, January 30, 2024

ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data. AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types. This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.

Key Points: 
  • ANN ARBOR, Mich., Jan. 30, 2024 /PRNewswire-PRWeb/ -- Advaita Bio was awarded $1.7 million from the National Institute of Health (NIH) to develop a new platform for the analysis of single-cell data.
  • AdvaitaBio is the leader in the interpretation of high-throughput biomedical data including variant interpretation, pathway analysis, disease subtype discovery, single cell analysis, and integration across multiple data types.
  • This research will develop advanced methods for the analysis of single cell and spatial genomics and transcriptomics data.
  • Advaita's Life Scientist and Principal Investigator, Cristiana Iosef, DVM, PhD, explains, "The world of single cell analysis is currently a jungle.

U.S. Company Announces Revolutionary AI Treatment for Alzheimer's at the Microcaps Conference

Retrieved on: 
Tuesday, January 23, 2024

Alzheimer's Treatment Centers of America (ATCA) only treats Alzheimer's, Dementia, Cognitive Impairment and Brain Fog from Long COVID, using Artificial Intelligence combined with Personalized Precision Medicine. In the study of its AI protocol, 75% of the patients had no further decline in their mild cognitive impairment.

Key Points: 
  • ATCA's mission to treat Alzheimer's, dementia, memory loss and brain fog from Long COVID that will reshape healthcare for the aging population.
    "
  • Alzheimer's Treatment Centers of America is not a start-up; it is a roll out and it is ready to scale.
  • Alzheimer's Treatment Centers of America uses Expert Artificial Intelligence (AI) technology with AI tools to create personalized care plans aimed at helping physicians improve patient care while also satisfying cognitive care guidelines.
  • Alzheimer's Treatment Centers of America has invested $1.5 million in onsite treatment tools and modalities, a pharma-grade nutraceutical store onsite, along with a 20-chair infusion center.

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Retrieved on: 
Monday, January 29, 2024

The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).

Key Points: 
  • The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).
  • These results warrant further development of ARM210 as a potential disease modifying treatment for RYR1-RM in a randomized, placebo-controlled Phase 2 trial.
  • We look forward to the next stages in the development of this important drug.”
    Further information about this Phase 1b trial can be found online at: https://clinicaltrials.gov/study/NCT04141670 .
  • Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial, Todd et al, eClinicalMedicine https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00012-9/fulltext

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Retrieved on: 
Monday, January 29, 2024

The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).

Key Points: 
  • The paper reviews data from the Phase 1b study of ARM210 and its novel allosteric mechanism of action (MoA) targeting the root cause of RYR1-RM: mutated Ryanodine Receptor 1 (RYR1).
  • These results warrant further development of ARM210 as a potential disease modifying treatment for RYR1-RM in a randomized, placebo-controlled Phase 2 trial.
  • We look forward to the next stages in the development of this important drug.”
    Further information about this Phase 1b trial can be found online at: https://clinicaltrials.gov/study/NCT04141670 .
  • Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial, Todd et al, eClinicalMedicine https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00012-9/fulltext

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

Retrieved on: 
Wednesday, January 24, 2024

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor’s proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines providing broader and more durable protection for COVID-19. As part of Project NextGen, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will conduct a Phase 1 clinical study with Capricor’s StealthX™ vaccine, subject to regulatory approval. NIAID's Division of Microbiology and Infectious Diseases (DMID) would oversee the study.

Key Points: 
  • As part of Project NextGen, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will conduct a Phase 1 clinical study with Capricor’s StealthX™ vaccine, subject to regulatory approval.
  • We view the NIH SARS-CoV-2 project as the first clinical step towards development of a next generation vaccine platform that may be extended to other infectious diseases.
  • Our platform is designed to combine the speed of response of an mRNA vaccine with the potential efficacy of a protein vaccine.
  • Further, our StealthX™ vaccine is free of both adjuvant and lipid nanoparticles and in preclinical studies has generated a strong immune response at low doses.